Geode Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.8K Hold
66,939
﹤0.01% 4285
2025
Q4
$58.5K Hold
66,939
﹤0.01% 4206
2025
Q3
$93.7K Hold
66,939
﹤0.01% 4147
2025
Q2
$51.7K Hold
66,939
﹤0.01% 4207
2025
Q1
$36.8K Hold
66,939
﹤0.01% 4246
2024
Q4
$61.2K Buy
66,939
+24,997
+60% +$26K ﹤0.01% 4208
2024
Q3
$36.5K Hold
41,942
﹤0.01% 4320
2024
Q2
$41.5K Hold
41,942
﹤0.01% 4318
2024
Q1
$44.5K Hold
41,942
﹤0.01% 4342
2023
Q4
$56.6K Hold
41,942
﹤0.01% 4317
2023
Q3
$91.4K Buy
41,942
+7,283
+21% +$17.8K ﹤0.01% 4277
2023
Q2
$90.1K Hold
34,659
﹤0.01% 4365
2023
Q1
$41.6K Hold
34,659
﹤0.01% 4558
2022
Q4
$56K Hold
34,659
﹤0.01% 4564
2022
Q3
$42K Hold
34,659
﹤0.01% 4798
2022
Q2
$34K Hold
34,659
﹤0.01% 4854
2022
Q1
$54K Hold
34,659
﹤0.01% 4790
2021
Q4
$48K Hold
34,659
﹤0.01% 4869
2021
Q3
$72K Buy
34,659
+10,114
+41% +$22.9K ﹤0.01% 4734
2021
Q2
$67K Hold
24,545
﹤0.01% 4622
2021
Q1
$92K Buy
24,545
+8,335
+51% +$24.9K ﹤0.01% 4318
2020
Q4
$38K Hold
16,210
﹤0.01% 4202
2020
Q3
$27K Buy
+16,210
New +$29.7K ﹤0.01% 4098

Other funds holding ONCY

Geode Capital Management's ONCY Position: Q1 2026 in Review

Geode Capital Management held its Oncolytics Biotech (ONCY) position steady in Q1 2026 at 66,939 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4285.

Geode Capital Management first reported a position in ONCY in Q3 2020 and has held it in 23 quarters since. The position peaked at $93.7K in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Geode Capital Management held 66,939 shares of Oncolytics Biotech worth $56.8K as of Q1 2026.
  • Geode Capital Management left its Oncolytics Biotech share count unchanged in Q1 2026.
  • Oncolytics Biotech made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4285 holding.
  • Geode Capital Management first reported a position in Oncolytics Biotech in Q3 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Oncolytics Biotech position peaked at $93.7K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.